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COPD is characterized by increased cough, mucus production, and airway inflammation.
Beating epithelial cell cilia contribute to mucociliary clearance with ciliary beat frequency
(CBF) an important measure of cilia function. However, whether CBF varies with COPD severity
is unknown. Aims: 1) to compare nasal cilia samples and their CBF from healthy non-smokers
(Control), COPD and At Risk (cough and sputum production) subjects. 2) to determine the
effect of pharmacologic agents that modulate mediators implicated in the pathogenesis of
COPD on nasal CBF. Nasal brushings of ciliated cells were obtained from Control, At Risk and
COPD subjects. Using high speed digital imaging, we measured baseline CBF ex vivo. Then,
CBF was re-measured after 30 min perfusion with pharmacologic agents that modulate medi-
ators implicated in COPD (salmeterol xinafoate, tiotropium bromide, licofelone, luteolin,
YM976, Defensin HNP-1) and again after 30 min washout. CBF was significantly depressed in
moderate and severe COPD compared to At Risk and Control subjects. There was an evident
and persistent rise in CBF with all agents tested in COPD cilia except that YM976 effects per-
sisted only in severe COPD. Only YM976 and tiotropium caused a persistent increase in CBF in
At Risk cilia. The reduction of nasal CBF in moderate and severe COPD implies that impaired
ciliary function may impact mucociliary clearance in COPD, potentially contributing to reten-
tion of secretions and infection. Pharmacologic agents with different mechanisms of action can
increase CBF of COPD cilia. Further investigation of the signalling pathways influencing CBF of
COPD cilia is needed.
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Chronic Obstructive Pulmonary Disease (COPD) is a respira-
tory disorder characterized by progressive, non-reversible
airflow limitation and usually is associated with a chronic
inflammatory response in the airways to harmful agents
e.g. tobacco smoke, pollutants and other irritants. Inflam-
matory cell infiltration of large airways and hyperplasia of
mucus glands, contribute to two characteristic symptoms of
COPD: cough and sputum production. These symptoms
usually precede development of airflow obstruction by
many years, sometimes identifying people at risk of
developing COPD.1,2 Recent studies demonstrated that
nasal epithelial cells can be used as surrogates for lower
airway epithelial cells. McDougall et al. (2008) showed that
inflammatory responses of nasal epithelial cells reflect
those of bronchial cells,3 and Sridhar et al. (2008) demon-
strated that smoking-induced gene expression changes in
the airway are reflected in the nasal epithelium.4 Hurst
et al. reported a correlation between the degree of
inflammation found in the upper and lower airways in
COPD, highlighting the potential relevance of studying
nasal epithelial cells in subjects with COPD.5
Ciliary beat frequency (CBF) and coordination are
important measures of ciliary function. We found that cilia
on nasal epithelial cells of 14 healthy volunteers (ages
22e59) beat with a frequency of 14.57  0.88 Hz and
exhibit a common metachronous beat pattern. Beat
frequencies have been shown to be similar in nasal,
tracheal and bronchial epithelial cells of subjects6,7 and
these frequencies were independent of age.7,8 Differences
in CBF have been documented in diverse patient pop-
ulations.9 Numerous agents have been shown to modulate
CBF10,11 with efficient mucociliary transport relying on
effective regulation of ciliary beating.12,13 In vitro, beta-
adrenergic and cholinergic agents were demonstrated to
stimulate CBF, while fluticasone, some preservatives and
some bacterial toxins inhibited CBF.10,11,14,15 However, the
direct effects of pharmacologic agents on CBF in epithelial
cells of COPD patients have not been well characterized. A
previous study of nasal CBF in stable COPD found that CBF
was reduced by 25% compared to healthy controls and that
salmeterol produced a significant increase in CBF.16
The aims of our study were to investigate whether
changes in ex vivo ciliary function were related to the level
of severity of COPD and to investigate how currently
available COPD therapies and experimental pharmacologic
agents might affect CBF. Some results from these studies
were previously reported as abstract(s).17,18
Methods
Study population
The research presented in this manuscript was done in
compliance with the Helsinki Declaration. The Research
Ethics Board of St. Joseph’s Healthcare Hamilton (SJHH)
approved the study protocols and consent forms. Male and
female subjects, aged 40e75, were recruited with adver-
tisements and from patients attending the Firestone Insti-
tute for Respiratory Health (Hamilton, ON, Canada).Subjects with differing severity of COPD as defined by the
original GOLD guidelines were studied: At Risk (n Z 7);
Moderate (n Z 5) and Severe/very severe COPD (n Z 7).2
Non-smoking, age-matched healthy volunteers (n Z 6)
with no history of respiratory disorders served as Controls.
All subjects were not withdrawn from their medications at
the time of study. All participants were non-atopic, had no
rhinitis and used no nasal therapy, and were studied when
clear of respiratory infections for at least four weeks
(verified by nasal swabs for bacteriology/virology on the
day nasal cilia were obtained). Please note that due to
limited resources, our experimental design did not include
comparing smoking to non-smoking subjects for each group.
The comparison was for Control (Healthy non-smokers)
compared to COPD subjects at different levels of COPD
severity independent of whether they were smokers or ex-
smokers.
Study sample collection and procedures/
assessments
After obtaining informed consent, subjects were charac-
terized using spirometry, body plethysmography, induced
sputum for cytology and bacterial analysis, allergy skin
test, and nasal swab (to test for respiratory viruses).
Cilia samples were obtained before sputum induction.
Subjects had two nasal brushings taken from the right or
left nostril, using a 3 mm bronchial cytology brush. Each
sample was suspended in 5 ml Earle’s Balanced Salt Solution
(EBSS) at 37 C for further examination.
Measurement of CBF
Nasal cilia samples were allowed to settle in the perfusion
chamber for 5 min, and then perfused with EBSS for
5e10 min to rinse out non-epithelial entities (blood or
inflammatory cells and debris). Ciliary beat frequency
(CBF) of nasal epithelial ciliated cells was determined at
37 C using published methods19 and as described in the
online supplement (Fig. 1s). Baseline CBF was measured
and results were expressed as mean frequency, in Hertz
(Hz). Then cells were used for testing pharmacologic
agents. CBF, epithelial cell size, coordination of beat, and
ciliary length were determined using ProAnalyst (XCitex,
MA, USA).
Measurements of the effect of pharmacologic
agents on CBF
The protocol involved 3 sequential steps: 1) baseline
perfusion with EBSS, 2) 30 min exposure perfusion to one of
the test agents, 3) 30 min EBSS washout perfusion to
determine the reversibility of the effects of the exposure
perfusion. All measurements were taken in the absence of
flow. For all epithelial samples, each CBF value was the
average CBF measured from 10 to 12 individual sites of
beating ciliated strips/clumps of cells. Each measurement
was made from each site consisting of at least 8 to 10 intact
ciliated cells. All drugs and vehicle controls (Methanol and
DMSO) were prepared in Earle’s Balanced Salt Solution
(EBSS) and the concentrations were final chamber
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not have any effect on CBF. Details on pharmacologic
agents used, their sources and doses are given in Table 1.
Data analysis
Data were plotted and analyzed using Prism 4 (GraphPad
Software Inc. CA, USA). All data were expressed as
mean  standard error of the mean (mean  SEM). The
baseline measurement for each subject was compared
between controls and the 3 groups (at risk, moderate, and
severe/very severe) and analysed using KruskaleWallis test
followed by Dunn’s Multiple Comparison Test. To determine
the effect of pharmacologic agents, data were expressed as
percentage of baseline CBF and were analyzed using ANOVA
followed by post comparison tests. For all tests, a p value
<0.05 was considered statistically significant.20
Additional details and references for the study protocol
and methods are provided in an online supplement.
Results
Characteristics of study subjects
A total of 6 healthy Control, 9 At Risk, 7 Moderate and 7
Severe COPD subjects were recruited for this study. Two At
Risk and two of the moderate subjects were excluded from
the study as their nasal samples contained no ciliated cells.
All subjects were maintained on their medications at the
time of study. All study subjects did not have allergies and
did not have any infections/colds as verified by sputum
sample bacteriology and nasal swab virology. Subjects were
grouped according to the GOLD criteria. All Control
subjects were non-smokers and all At Risk and COPD
subjects were smokers or ex-smokers with more than 32
pack years. Demographics for all subjects are presented in
Table 2.
Sputum
Sputum data from study subjects who were able to provide
an induced sputum sample are summarized in Table 3. Total
cell count was significantly higher in sputum from Moderate
and Severe COPD subjects compared to sputum fromTable 1 Pharmacologic agents and the concentrations tested.
Drug/Agent Sup
Current Bronchodilators
Salmeterol xinafoate: a long-acting beta adrenergic agonist Sigm
Tiotropium bromide: a long-acting anti-cholinergic drug Boe
Inge
Experimental Pharmacologic Agents
Licofelone: a cyclooxygenase/Lipoxygenase Inhibitor Cay
Luteolin: inhibits MMP2 and MMP9 Cay
YM 976: a phosphodiesterase-4 inhibitor Sigm
Defensin HNP-1: endogenous antimicrobial peptide Sigm
*Oakville, ON, Canada, yAnn Arbor, MI, USA, # USA (purchased at hospControls. Macrophages were significantly lower in sputum
from Severe COPD compared to At Risk subjects. Neutro-
phils and eosinophils were not significantly different among
the groups.
CBF, cilia samples and coordination
CBF was significantly depressed in moderate and severe
COPD subjects compared to At Risk and Control subjects,
but the reduced CBF of nasal epithelium did not correlate
with the severity of disease (Fig. 1). Cell size and cilia
length were not significantly different among the groups
studied There was no significant difference in cilia length
and cell size of ciliated epithelial cells obtained from
Control and COPD subjects (Fig. 2). A quantitative analysis
of the cilia samples studied demonstrated a higher percent
of strips/clumps of uncoordinated ciliated cells compared
to coordinated ciliated cells in all study subjects (Fig. 3).
Percent (%) uncoordinated ciliated strips/clumps from
Moderate COPD subjects were significantly less compared
to those from Control subjects. Very few non-beating strips
of cilia were observed in all samples and were not different
among the groups. The percentage of non-ciliated epithe-
lial strips/clumps of cells was significantly higher in nasal
samples from Moderate and Severe subjects compared to
Control subjects (Fig. 3).
Effect of pharmacologic agents on CBF
Fig. 4A describes the protocol used for measuring the effect
of pharmacologic agents on CBF. CBF recordings from 10 to
12 strips/clumps of ciliated cells per sample at each time
point were recorded for a total of 30e36 independent CBF
values per experiment per agent tested. Fresh cells were
used for each treatment. Fig. 4B shows the effect of the
agents tested on CBF of nasal cilia brushed from Control, At
Risk, Moderate and Severe COPD subjects. Since agent/
post-agent values were not significantly different, these
data were analyzed for group effect using ANOVA followed
by Bonferroni’s Multiple Comparison Test. The % baseline
CBF in COPD and At Risk cilia that were treated with drugs
was compared to the % baseline CBF in Control cilia treated
with the same drugs. We observed an evident and persis-
tent (after EBSS washout, post-agent) rise in CBF to allplier Vehicle Final Concentration
in EBSS
References
aeAldrich* methanol 1.0 mM 16
hringer
lheim#
methanol 5.0 mM 32
man Chemicaly DMSO 10.0 mM 36,37
man Chemicaly DMSO 100.0 mM 39
aeAldrich* DMSO 100.0 mM 41
aeAldrich* DMSO 6 mM 43
ital pharmacy).
Table 2 Characteristics of the Study Population.
Control At Risk Moderate COPD Severe/very severe COPD
Number of subjects 6 7 5 7
Gender (M/F) 5/1 3/4 2/3 5/2
Caucasian/non-caucasian 5/1 6/1 5/0 7/0
Age (yr) 54  4 52  3 65  3 62  3
Smoking history NS 4S, 3xS 2S, 3xS 2S, 5xS
Pack/yr 0 32  6*** 48  11*** 54  9*** yy
Weight (Kg) 90  8 83  6 84  4 80  7
Height (cm) 175  2 165  4 164  3 170  3
Pulmonary function tests, % predicted
FVC 106  7 97  6 84  6 ** 70  7*** yyy
FEV1 104  7 98  4 60  3*** yyy 30  4*** yyy zzz
FEV1/FVC 78  3 81  2 58  5 * yy 34  4 *** yyy zz
FVC (post-salbutamol) 104  8 99  5 83  6 ** 73  6*** yyy
FEV1(post-salbutamol) 105  8 100  4 60  3*** yyy 33  6*** yyy zzz
FEV1/FVC(post-salbutamol) 80  2 82  2 58  3** yy 36  5*** yyy zz
TLC (L) 6.4  0.6 5.3  0.5 5.9  0.6 6.9  0.4
DLCO (ml/min/mmHg) 25  2 22  2 17  3*** y 13  1*** yyy z
Two-way ANOVA followed by Bonferroni post-tests *P < 0.05, **P < 0.01, ***P < 0.001 compared to Control; yP < 0.05, yyP < 0.01,
yyyP < 0.001 compared to At Risk; zzP < 0.01, zzzP < 0.001 compared to Moderate COPD. All values are mean  SEM. NS: non-smoker,
S: smoker, xS: ex-smoker; TLC: total lung capacity; DLCO: diffusion capacity of the lung for carbon monoxide.
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COPD, except that the YM976 effects persisted only in
Severe COPD, and the effects of luteolin and HNP-1 on nasal
cilia from Moderate COPD did not reach significance. Only
YM976 and tiotropium bromide caused a similar effect
(increased and persistent rise in CBF) in cilia from At Risk
subjects compared to cilia from Control subjects.
Discussion
Airway epithelial cell cilia are motile cilia that by virtue of
their coordinated beating transport mucus up the respira-
tory tract. Little is known about a specific role for cilia in
COPD. Two characteristic features of COPD, cough and
sputum production indicate ciliary dysfunction and
prompted us to investigate the role of the ciliated epithe-
lium in this disease. We used a High Speed Digital imaging
system to obtain ex-vivo measurements of CBF and related
parameters (cell size, cilia length, cilia abundance and
coordination) of fresh nasal ciliated epithelial cells in an
accurate and reproducible manner. Using this system, CBFTable 3 Sputum Cell Counts of Study Subjects.
Control At Ri
Number of subjects 3 7
Total cells/sputum weight, (x105/ml) 22  2.5 62.6
Squamous cells (%) 20.3  8.9 9.6 
Neutrophils (%) 51  9.2 47.4
Eosinophils (%) 0.3  0.2 0.2 
Macrophages (%) 43.5  8.1 51.1
Lymphocytes (%) 3.2  1.1 1.2 
Bronchial epithelial (%) 1.7  0.2 0.1 
Two-way ANOVA followed by Bonferroni post-tests ***P < 0.001 compar
values are mean  SEM.was measured directly to assess baseline cilia function,
followed by a determination of the effect of pharmacologic
agents in cilia from several populations: healthy non-
smoker Controls, At Risk, and COPD subjects. CBF (Hz or
beats/s) was significantly depressed in Moderate and
Severe COPD compared to At Risk and Control subjects. The
reduction of nasal CBF in Moderate and Severe COPD
patients suggests that epithelial cell cilia function may
impact mucociliary clearance in these COPD patients,
contributing to retention of secretions and cough, and
potential airway infection. Cell size, cilia length, and cilia
coordination did not appear to contribute to the depressed
CBF observed in our Moderate and Severe COPD cilia
samples. A higher % of non-ciliated epithelial cells as
observed in the Moderate and Severe groups in vitro, might
indicate epithelial remodeling and could play a role in
altered ciliary function in vivo. When investigating the
effect of pharmacologic agents that modulate mediators
implicated in COPD, we observed that agents with different
mechanisms of action can similarly modulate nasal CBF of
COPD subjects, especially cilia from severe COPD comparedsk Moderate COPD Severe/very severe COPD
4 4
 11.8 107.8  51.3*** y 111  37.8***y
8.1 0.4  0.2 3.9  3.7
 10.5 64.8  16.9 69.5  18.7
0.2 14.5  13.2 16.2  15.5
 10.4 20.1  5.6 13.9  3.4y
0.7 0.3  0.3 0.5  0.3
0.1 0.5  0.5 0.0  0.0
ed to Control; yP < 0.05 compared to At Risk. %Z % total cells. All
Figure 2 Cell diameterandcilia lengthofnasal ciliaofControl,
At Risk and COPD subjects. Cell diameter (mm) and cilia length
(mm)of nasal samples ofControl subjects (nZ 6), At Risk subjects
(nZ 7), Moderate (nZ 5) and Severe (nZ 7) COPD subjects.
Figure 1 CBF of nasal cilia of Control, At Risk and COPD
subjects. CBF (Hz) of ciliated nasal epithelium of Control
(n Z 6), At Risk (n Z 7) and COPD subjects (Moderate, n Z 5
and Severe, n Z 7). *p Z 0.029, KruskaleWallis test. For all
epithelial samples, each CBF value is the average CBF
measured from 10 to 12 individual sites. Data are the
mean  SEM of n where n Z number of subjects.
Figure 3 Cilia samples and coordination of nasal cilia of
Control, At Risk and COPD subjects. Cilia samples and coordi-
nation of cilia of nasal epithelium of Control healthy subjects
(nZ 6), At Risk subjects (nZ 7), Moderate (nZ 5) and Severe
(n Z 7) COPD subjects. Data are expressed as % total number
of epithelial strips/clumps studied which ranged from 55 to 77
strips/clumps per subject. * 2-way ANOVA followed by Bon-
ferroni post-tests P < 0.05 compared to Control.
Ciliary beat frequency is depressed in COPD 1143to Control subjects. Further investigation of cilia function
and structure and the effects of the pharmacologic agents
on airway epithelial cilia in COPD are needed.
Characteristics of study subjects
All subjects were studied when they were clear of respi-
ratory infections for at least four weeks. The bacteriology
and virology outcomes verified this criterion when the nasal
samples were obtained. This is of importance as bacterial
and viral products have been shown to affect cilia function
and structure.14,21,22 We did not recruit subjects who were
atopic as changes in CBF have been demonstrated in nasal
cilia of subjects taking anti-allergy medications.23 Total cell
count was significantly higher in sputum from Moderate and
Severe COPD subjects compared to sputum from healthy
Controls indicating some degree of inflammation in the
COPD subjects. However, the inflammation in these COPD
subjects appears to be well controlled since sputum
neutrophils and eosinophils were not significantly different
from those in Control and At Risk subjects. This suggests
that infection, allergy or presence of inflammatory cells do
not contribute to the reduced CBF observed in COPD cilia.
CBF, cilia samples and coordination
Mucociliary clearance has been shown to be increased in
smokers, and nasal CBF was recently reported to be
increased24 or decreased25 by cigarette smoke exposure,
confusing the interpretation of the link between CBF,
smoking and MCC. Additionally, in a study of bronchial
Figure 4 Effect of pharmacologic agents on CBF of nasal cilia of Control, At Risk and COPD subjects. CBF (Hz) was measured as
indicated in experimental protocol (A): Post-agent: washout of agent from chamber where nasal cilia were placed. (B) Data are
mean  SEM of % baseline CBF. Numbers above bars indicate the number of subjects. ANOVA followed by Bonferroni’s Multiple
Comparison Test: *p < 0.05 vs Control, #p < 0.05 vs At Risk.
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Ciliary beat frequency is depressed in COPD 1145epithelium from normal smokers and matched non-
smokers, smoking caused a decline in the proportion of
ciliated cells.26 In our study, the observed reduction in CBF
was independent of the effects of cigarette smoke since
CBF of cilia from At Risk subjects (smokers/ex-smokers) was
not significantly different from non-smoker Controls. In
lung disease, the remodelling of the airway epithelium may
considerably disturb its functions. Many processes including
inflammation, apoptosis, protease/anti-protease imbal-
ance, and oxidative stress changes contribute to the
pathobiology of COPD.27e29 In addition, the ciliated cells,
which provide the mechanism for moving the mucus up the
airway surface, have also been reported to be involved in
epithelial cell transdifferentiation and repair.30 These
processes of remodelling and repair might explain the
higher % of non-ciliated epithelial cells observed in our
COPD samples and could have relevance to cilia function
in vivo. However, in our in vitro study, we measured CBF
from 10 to 12 ciliated strips of 8e10 cells each with beating
cilia, and avoided areas of non-ciliated cells in all the
samples studied. Although the reduced CBF (beats/s) of
nasal cilia from COPD patients is small, it is significant and
has potential clinical significance when considering clear-
ance of secretions over hours. Future studies are needed to
determine the mechanisms which modulate cilia function in
COPD subjects.
An earlier analysis of bronchial epithelium revealed
a significant (10e15%) reduction in cilia length of healthy
smokers and COPD smokers compared to healthy non-
smokers.31 In our study, CBF was significantly depressed in
cilia obtained from moderate and severe COPD subjects
compared to At Risk and Control subjects. This significant
decline in CBF was not due to a difference in the quality of
samples, or to cell size, cilia length or cilia coordination. In
addition, since At Risk, and COPD (Moderate, Severe)
subjects were smokers/ex-smokers with minimum of 32
pack years, the reduced CBF in COPD cilia only cannot be
attributed just to the effect of cigarette smoke.Effect of pharmacologic agents on CBF
We investigated the effect of two bronchodilators that are
currently used in treatment of COPD: salmeterol xinafoate
and tiotropium bromide.2 Salmeterol xinafoate, a long-
acting beta adrenergic agonist, was used at a therapeutic
concentration that has also been shown to produce the
maximum increase in CBF of nasal epithelium obtained
from COPD patients.16 Tiotropium bromide, a long-acting
anti-cholinergic drug, was used at a concentration that
corresponds to the therapeutic dose used in COPD.2,32 In
addition, we investigated the effects of four experimental
pharmacologic agents which inhibit mediators or pathways
that have been shown to be involved in the pathogenesis of
COPD2,33e35: 1) Licofelone (10.0 mM), a cyclooxygenase/
lipoxygenase inhibitor,36 shown to inhibit the cyclo-
oxygenase/lipoxygenase pathways in vitro,37 was used as
exhaled leukotrienes and prostaglandins have been shown
to be elevated in COPD.38 2) Luteolin, inhibits matrix
metalloproteinases. Specifically, it is an inhibitor of matrix
metalloproteinase-2 and -9 at 100 mM39 and we used it since
matrix metalloproteinases have been related to COPDprogression.33,40 3) YM 976 (100 nM), a phosphodiesterase-4
inhibitor41 modulates cAMP which is one of the main
intracellular second messengers that regulate CBF.42 4)
Defensin HNP-1 (6 mM), an endogenous antimicrobial
peptide which inhibits antiproteinase activity of serpins
(serine proteinase inhibitors), was also tested since
defensins have been investigated in the pathogenesis of
COPD.43 All the agents have been shown to be effective at
inhibiting the corresponding pathways in vitro at the
concentration used in this study. Note that the significant
increase of CBF of cilia from COPD subjects in response to
the agents tested indicated that agents with different
mechanisms of action can similarly modulate CBF of nasal
cilia of COPD subjects. The persistent effect of YM976 on
cilia from Severe but not Moderate COPD subjects might
suggest an additional role for the cAMP pathway in Severe
COPD cilia. Roflumilast (a phosphodiesterase-4 inhibitor)
has recently been shown to improve lung function in
patients with moderate and severe COPD treated with sal-
meterol or tiotropium44 supporting our conclusion. Specific
receptors and ion channel proteins are contained in cilia
membranes and these initiate signaling pathways control-
ling motility, mechanical or chemical stimuli.42,45 CBF in
airway epithelial cells depends on the cyclic nucleotides
cAMP and cGMP and intracellular calcium concentration.46
In human airway epithelia, soluble adenylyl cyclase (sAC)
is localized to motile airway cilia and it contributes to the
regulation of human airway CBF.47 Additional research is
required to determine the structural-functional regulation
of CBF via all signaling pathways42 and how this might
influence the initiation or progression of lung diseases
including COPD.
In conclusion, factors affecting mucus transport fall into
two groups: those affecting the cilia and those affecting
mucus. Here we investigated the role of cilia in COPD and
demonstrated a significant decline in CBF of cilia obtained
from Moderate and Severe COPD subjects that could be
clinically relevant. Pharmacologic agents with different
mechanisms of action can similarly increase CBF of nasal
cilia of COPD subjects compared to Control subjects.
Therefore, whether the agent modulates a receptor
(adrenergic/cholinergic), an enzyme (5-Lipoxygenase,
cyclooxygenase, phosphodiesterase-4, serpins) or struc-
tural components (MMPs soluble and cell surface forms),
the final outcome is an increased CBF. Further investigation
of the signaling pathways involved is needed. Continued
investigation of the function and structure of airway
epithelial cilia in COPD could lead to a better under-
standing of the mechanisms of disease and to improved
therapies.Grants
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